mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment

In conclusion, in the majority of pNETs that progress on rapalogs, it is possible to reduce disease progression using an mTORKi, such as CC-223. Moreover, CC-223 had an additional transient cardiac benefit on valvular fibrosis compared with placebo- or rapalog-treated mice. These results provide the preclinical rationale to further develop mTORKi clinically upon progression on rapalog therapy and to further test their long-term cardioprotective benefit in those NET patients prone to carcinoid syndrome. Mol Cancer Ther; 16(11); 2432–41. ©2017 AACR.

Source: Molecular Cancer Therapeutics - November 1, 2017 Category: Cancer & Oncology Authors: Orr-Asman, M. A., Chu, Z., Jiang, M., Worley, M., LaSance, K., Koch, S. E., Carreira, V. S., Dahche, H. M., Plas, D. R., Komurov, K., Qi, X., Mercer, C. A., Anthony, L. B., Rubinstein, J., Thomas, H. E. Tags: Small Molecule Therapeutics Source Type: research